PRIMARY OBJECTIVE:
I. To determine the overall response rate (ORR) of patients with advanced non-small cell lung
cancer (NSCLC) treated with pevonedistat (MLN4924 [pevonedistat]) in combination with
carboplatin and paclitaxel.
SECONDARY OBJECTIVES:
I. To estimate the progression-free survival (PFS) of patients with advanced NSCLC treated
with MLN4924 (pevonedistat) in combination with carboplatin and paclitaxel.
II. To estimate the overall survival (OS) of patients with advanced NSCLC treated with
MLN4924 (pevonedistat) in combination with carboplatin and paclitaxel.
III. To evaluate the safety profile of MLN4924 (pevonedistat) in combination with carboplatin
and paclitaxel.
CORRELATIVE OBJECTIVES:
I. To evaluate expression of nuclear factor-erythroid 2 p45-related factor 2 (NRF2) target
genes NAD(P)H: quinone oxidoreductase1 (NQO1) and the cysteine/glutamate antiporter solute
carrier family 7 member 11 (SCL7A11).
II. To determine expression of pharmacodynamic markers induced by neural precursor cell
expressed developmentally downregulated protein 8 (NEDD-8) activating enzyme (NAE)
inhibition: cyclic AMP-dependent transcription factor (ATF3), beta 2 microglobulin (B2M),
glutamate-cysteine ligase regulatory subunit (GCLM), glutathione-disulfide reductase (GSR),
deoxyribonucleic acid (DNA)-3-methyladenine (MAG1), ribosomal protein lateral stalk subunit
P0 (RPLPO), sulfiredoxin-1 (SRXN1), thioredoxin reductase 1 (TXNRD1), and
ubiquitin-conjugating enzyme (UBC).
III. To perform qualitative assessment of tumor NAE1 and ubiquitin-conjugating enzyme E2 M
(UBC12) protein expression at baseline.
IV. To assess circulating tumor cells (CTCs) for DNA damage repair pathway alterations (i.e.,
gamma H2AX induction, RAD51).
V. To evaluate pharmacokinetic (PK) parameters of MLN4924 (pevonedistat) when given in
combination with paclitaxel and carboplatin.
OUTLINE:
Patients receive paclitaxel intravenously (IV) over 3 hours on day 1, carboplatin IV over
30-60 minutes on day 1, and pevonedistat IV over 1 hour on days 1, 3, and 5. Treatment
repeats every 21 days for at least 4 cycles in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, all patients without disease progression are followed up
at 30 days, every 3 months for 1 year and then every 6 months until 5 years from end of study
treatment.
Inclusion Criteria:
- Patients must be >= 18 years old. Because no dosing or adverse event (AE) data are
currently available on the use of MLN4924 (pevonedistat) in combination with
carboplatin and paclitaxel in patients < 18 years of age, children are excluded from
this study, but may be eligible for future pediatric trials.
- Patients must have histologically confirmed stage IIIB or IV NSCLC (squamous or
nonsquamous) that is metastatic or unresectable.
- Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1.
- Patients must have progressed on prior treatment with checkpoint inhibitor (PD-1/PD-L1
inhibitors) either as a single-agent therapy or in combination, as below. Patients
will be eligible if there is a contra-indication to checkpoint inhibitor therapy.
- Patients who have progressed after receiving a checkpoint inhibitor in
combination with a platinum-based doublet, as first-line treatment for NSCLC.
- Patients who have progressed on checkpoint inhibitor as second-line therapy,
after receiving a platinum-based doublet as first-line therapy.
- Patients who have progressed on platinum-based doublet as second-line therapy,
after receiving a checkpoint inhibitor as first-line therapy.
- Patients must have disease progression on or after platinum-based chemotherapy for
metastatic disease or within 6 months of completion of platinum-based chemotherapy
administration as adjuvant/neoadjuvant chemotherapy or concurrent chemoradiation.
- Absolute neutrophil count >= 1,500/mcL.
- Platelet count >= 150,000/mcL.
- Total bilirubin =< 1 x institutional upper limit of normal (ULN). Patients with
Gilbert's syndrome may enroll if direct bilirubin =< 1.5 x institutional ULN.
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) /
alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x
institutional ULN. Patients with metastatic liver disease may enroll if =< 5 x ULN.
- Glomerular filtration rate (GFR) > 30 mL/min/1.73 m^2.
- Known human immunodeficiency virus (HIV) positive patients who meet the following
criteria will be considered eligible:
- CD4 count > 350 cells/mm^3.
- Undetectable viral load within the last six months.
- HIV positive patients must be stable on highly active antiretroviral therapy
(HAART). Clinically significant metabolic enzyme inducers are not permitted
during this study (e.g., ritonavir, efavirenz, nevirapine).
- No history of acquired immune deficiency syndrome (AIDS)-defining opportunistic
infections.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Life expectancy >= 12 weeks.
- Patients are eligible if central nervous system (CNS) metastases are adequately
treated and neurological symptoms have returned to baseline or are controlled for at
least 2 weeks prior to enrollment. In addition, subjects must be either off
corticosteroids, or on stable or decreasing dose of steroids. Patients with
leptomeningeal disease are excluded.
- The effects of MLN4924 (pevonedistat) on the developing human fetus are unknown. For
this reason and because agents as well as other therapeutic agents used in this trial
are known to be teratogenic, women of child-bearing potential and men must agree to
use adequate contraception (hormonal or barrier method of birth control; abstinence)
prior to study entry and for the duration of study participation. Should a woman
become pregnant or suspect she is pregnant while she or her partner is participating
in this study or within 4 months of completion, she should inform her treating
physician immediately. Men treated or enrolled on this protocol must also agree to use
adequate contraception prior to the study, for the duration of study participation,
and 4 months after completion of MLN4924 (pevonedistat) administration.
Female patients who:
- Are postmenopausal for at least 1 year before the screening visit, or
- Are surgically sterile, or If they are of childbearing potential,
- Agree to practice 1 highly effective method and 1 additional effective (barrier)
method of contraception, at the same time, from the time of signing the informed
consent through 4 months after the last dose of study drug (female and male condoms
should not be used together), or
- Agree to practice true abstinence, when this is in line with the preferred and usual
lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation,
symptothermal, postovulation methods] withdrawal, spermicides only, and lactational
amenorrhea are not acceptable methods of contraception.) Male patients, even if
surgically sterilized (i.e., status postvasectomy), who
- Agree to practice effective barrier contraception during the entire study treatment
period and through 4 months after the last dose of study drug (female and male condoms
should not be used together), OR
- Agree to practice true abstinence, when this is in line with the preferred and usual
lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation,
symptothermal, postovulation methods for the female partner] withdrawal, spermicides
only, and lactational amenorrhea are not acceptable methods of contraception.)
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV
viral load must be undetectable on suppressive therapy, if indicated.
- Patients with a history of hepatitis C virus (HCV) infection must have been
treated and cured. For patients with HCV infection who are currently on
treatment, they are eligible if they have an undetectable HCV viral load.
- Patients with a prior or concurrent malignancy whose natural history or treatment
does not have the potential to interfere with the safety or efficacy assessment
of the investigational regimen are eligible for this trial.
- Left ventricular ejection fraction (LVEF) >= 50% as assessed by echocardiogram or
radionuclide angiography.
- Ability to understand and the willingness to sign a written informed consent
document. Participants with impaired decision-making capacity (IDMC) who have a
legally authorized representative (LAR) or caregiver and/or family member
available will also be considered eligible.
- Patients with NSCLC harboring genomic aberrations (e.g. sensitizing EGFR, ALK,
ROS1, NTRK, BRAF V600E mutation positive) must have received prior treatment with
Food and Drug Administration (FDA) approved targeted therapy for patients for
which FDA approved targeted therapies is available.
Exclusion Criteria:
- Patients who have not recovered from AEs due to prior anti-cancer therapy (i.e., have
residual toxicities > grade 1) with the exception of alopecia and neuropathy.
- Patients who are receiving any other investigational agents.
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to MLN4924 (pevonedistat), carboplatin, or paclitaxel.
- Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study.
- Patients with uncontrolled intercurrent illness.
- Patients with psychiatric illness/social situations that would limit compliance with
study requirements.
- Pregnant women are excluded from this study because MLN4924 (pevonedistat),
carboplatin, and paclitaxel have the potential for teratogenic or abortifacient
effects. Because there is an unknown but potential risk for adverse events in nursing
infants secondary to treatment of the mother with MLN4924 (pevonedistat),
breastfeeding must be discontinued if the mother is treated with MLN4924
(pevonedistat). These potential risks may also apply to other agents used in this
study.
- Female patients who intend to donate eggs (ova) during the course of this study or 4
months after receiving their last dose of study drug(s).
- Male patients who intend to donate sperm during the course of this study or 4 months
after receiving their last dose of study drug(s).
- Known cardiopulmonary disease defined as:
- Unstable angina;
- Congestive heart failure (New York Heart Association [NYHA] class III or IV;);
- Myocardial infarction within 6 months prior to first dose (patients who had
ischemic heart disease such as acute coronary syndrome [ACS], myocardial
infarction, and/or revascularization greater than 6 months before screening and
who are without cardiac symptoms may enroll);
- Symptomatic cardiomyopathy;
- Clinically significant arrhythmia:
- History of polymorphic ventricular fibrillation or torsade de pointes,
- Permanent atrial fibrillation, defined as continuous atrial fibrillation for
>= 6 months,
- Persistent atrial fibrillation, defined as sustained atrial fibrillation
lasting > 7 days and/or requiring cardioversion in the 4 weeks before
screening,
- Grade 3 atrial fibrillation defined as symptomatic and incompletely
controlled medically, or controlled with device (e.g., pacemaker), or
ablation in the past 6 months and
- Patients with paroxysmal atrial fibrillation or grade < 3 atrial
fibrillation for period of at least 6 months are permitted to enroll
provided that their rate is controlled on a stable regimen.
- Clinically symptomatic pulmonary hypertension requiring pharmacologic therapy.
- Peripheral neuropathy that is grade >= 3, or grade 2 with pain on clinical examination
during the screening period.
- Uncontrolled high blood pressure (i.e., systolic blood pressure > 180 mmHg, diastolic
blood pressure > 95 mmHg).
- Prolonged rate corrected QT (QTc) interval >= 500 msec, calculated according to
institutional guidelines.
- Known moderate to severe chronic obstructive pulmonary disease, interstitial lung
disease, and pulmonary fibrosis.
- Major surgery within 14 days before the first dose of any study drug or a scheduled
surgery during study period.
- Life-threatening illness unrelated to cancer.
- Patients with uncontrolled coagulopathy or bleeding disorder.
- Known hepatic cirrhosis or severe pre-existing hepatic impairment.
